Summary & Overview
HCPCS G9431: Pathology Report Missing Key Elements for Invasive Tumors
HCPCS Level II code G9431 flags pathology reports for invasive skin tumors that omit critical prognostic details: patient category, tumor thickness, ulceration and mitotic rate, peripheral and deep margin status, and microsatellitosis. Accurate and complete pathology reporting affects staging, prognosis, and downstream treatment planning for invasive cutaneous malignancies, making documentation standards nationally important for clinical care and appropriate utilization of follow-up services.
This analysis covers payer approaches from major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of what the code represents, the clinical and reporting context for use, typical sites of service, and which stakeholders commonly encounter the code. The publication also outlines the types of benchmarks and policy updates that inform how payers and institutions monitor pathology reporting completeness, and highlights clinical implications for surgical teams and pathologists.
The content is intended for a national audience of clinicians, coding and billing professionals, and policy analysts seeking concise guidance on the code’s purpose and relevance. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code G9431 indicates that a pathology report for an invasive skin tumor does not include essential prognostic elements: patient category, tumor thickness, ulceration and mitotic rate, peripheral and deep margin status, and presence or absence of microsatellitosis. The service type is pathology report review / surgical pathology reporting, and the typical site of service is pathology laboratory or hospital/ambulatory surgical setting where surgical specimens are processed and reported.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient presents to dermatology with a progressively enlarging pigmented lesion on the forearm that was biopsied in an outpatient clinic. The specimen is submitted to surgical pathology after an excisional biopsy. The pathology report documents diagnosis of invasive cutaneous melanoma but omits key staging and prognostic elements: the pathologic tumor (pT) category, Breslow thickness, presence or absence of ulceration and mitotic rate, status of peripheral and deep margins, and presence or absence of microsatellitosis. The clinical workflow includes specimen accessioning, gross description, microscopic evaluation with measurement of tumor thickness, assessment for ulceration and mitotic activity, margin inked evaluation, and reporting of microsatellitosis when present. Treating clinicians (dermatologic surgeons, medical oncologists, and primary care providers) rely on these data for staging, surgical planning (wide local excision with appropriate margins), consideration of sentinel lymph node biopsy, and systemic therapy decisions. Typical site of service is an outpatient dermatology clinic or ambulatory surgical center with pathology services provided by hospital or independent pathology laboratories.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When work required is substantially greater than typical for the associated service (rarely applicable to pathology report content deficiencies). |